Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorSironax USA, Inc.
About this trial
This Phase 2, open-label study will evaluate the safety, tolerability, and pharmacokinetics of SIR2501 in adults with solid tumors who are scheduled to receive paclitaxel-based chemotherapy. The study will also explore whether SIR2501 has the potential to reduce the development of chemotherapy-induced peripheral neuropathy (CIPN).
Eligibility criteria
Qualifiers
Adults ≥18 years with confirmed solid tumors
Planned treatment with paclitaxel-based chemotherapy
ECOG performance status 0-2
Disqualifiers
Pre-existing peripheral neuropathy
Conditions or medications that may interfere with neuropathy assessment
Prior exposure to neurotoxic chemotherapy
Use of medications known to mitigate CIPN
Trial design
Treatments tested in this trial
- SIR2501
Treatment groups
18 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov